Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

Immunosuppressive Myeloid Cells Can Be Modulated with NRP2-Targeting Antibody ATYR2810 Leading to Enhanced Anti-Tumor Immunity

Tuesday, April 29, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the potential of the NRP2-targeting antibody ATYR2810 in modulating immunosuppressive myeloid cells, which may enhance anti-tumor immunity. This development could represent a significant advancement in cancer treatment strategies. The focus on myeloid cell modulation highlights a novel approach to improving immune responses against tumors.
Price reaction · baseline $3.27 (2025-04-28 close) · hit pre-market · clean, no other ATYR news in the window
day 0 close · peak
+3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • NRP2-targeting antibody ATYR2810 shows promise in modulating myeloid cells.
  • Enhanced anti-tumor immunity could lead to better treatment outcomes.
  • Potential for innovative approaches in cancer therapy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What is ATYR2810?

ATYR2810 is an NRP2-targeting antibody that modulates myeloid cells.

How does ATYR2810 enhance anti-tumor immunity?

It modulates immunosuppressive myeloid cells, potentially improving immune responses.

What is the significance of myeloid cell modulation?

Modulating myeloid cells can lead to enhanced anti-tumor immunity and better treatment outcomes.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare NRP2 anti-tumor immunity myeloid cells cancer therapy
Last updated: Apr 29, 2025

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →